56results about "Ether/acetal active ingredients" patented technology

The present invention relates to an oral anti-ageing composition comprising a mixture of: - At least one ingredient chosen from the group of niacinamide mononucleotide (NMN), niacinamide riboside (NR) and niacin - Resveratrol and / or pterostilbene - Pomegranate extract and / or - Sulforaphane or a source of sulforaphane; and - Vitamin D.

The present invention relates to obesity control by regulating the expression level of TREK1.

The present invention relates to an AMPK activator comprising 1,1-diethoxyethane as an active ingredient, and uses thereof. More specifically, the present invention relates to an AMPK activator comprising 1,1-diethoxyethane (1,1-DEE) as an active ingredient, and uses thereof, for example, as a pharmaceutical composition, a cosmetic composition, a food composition, or a feed composition, which is a composition for preventing, treating, or alleviating diseases requiring AMPK activation, and for anti-aging, lifespan extension, or physical vitality enhancement.

The application belongs to the technical field of natural medicinal chemistry, and relates to the use of a dibenzazepine compound in mistletoe in the preparation of a medicine for preventing or treating rheumatoid arthritis. In vitro experiments show that the use of the compound alone has different degrees of inhibitory effect on the proliferation of primary rat synovial fibroblasts, and the inhibitory effect is synergistically enhanced when the compound 2 is used in combination with mistletoe lectin. Animal experiments show that the use of the compound alone has different degrees of inhibitory effect on the joint swelling of a collagen-induced rat arthritis model, and the inhibitory effect of some dibenzazepine compounds is close to or better than that of a positive medicine, and the inhibitory effect of the compound 2 used in combination with mistletoe lectin on the joint swelling of the right hind foot of a rat is synergistically enhanced. In summary, the dibenzazepine compound in mistletoe has the potential to be developed into a medicine for treating rheumatoid arthritis, can provide more choices for clinical treatment, and has important social benefits and economic value.

To provide SARS-CoV-2 inactivating agents showing excellent SARS-CoV-2 inactivating effect.SOLUTION: Provided is a SARS-CoV-2 inactivating agent containing a polyoxyethylene alkyl ether having an alkyl group with 12 carbon atoms and an average molar addition number of ethylene oxide of 8 or less, as an active ingredient, the concentration of the polyoxyethylene alkyl ether being 150 ppm or more and less than 2000 ppm.SELECTED DRAWING: None

A minimally invasive method for the reduction of hypertension is provided using focused ultrasound. After injection of ultrasound-responsive nanodroplets loaded with a therapeutic agent (e.g. barbiturates), focused ultrasound is delivered to a norepinephrine-producing region, such as the periaqueductal gray region, thereby locally releasing the therapeutic agent payload from the nanodroplets and achieving a therapeutic reduction in blood pressure. Acoustic emissions from vaporizing droplets may be employed, for example, to infer one or more therapeutic parameters based on a pre-established correlation. For example, plasma hormone content and / or the change in blood pressure may be inferred, thereby providing a means of real-time treatment monitoring. The present example methods may be employed to achieve a reduction in blood pressure for subjects exhibiting drug-resistant hypertension.

The application discloses application of bisferenone 2 in preparation of a drug for treating renal fibrosis. The application first proposes and verifies that bisferenone 2 can effectively inhibit iron death of renal tubular epithelial cells to restore cell activity, delay epithelial-mesenchymal cell transformation, down-regulate expression of fibrosis-related proteins, relieve renal injury, effectively alleviate renal fibrosis progression, and has an excellent application prospect in clinical treatment of renal fibrosis.

Disclosed herein are compositions comprising a GLP-1R agonist composition, a DPP-4 inhibitor composition, or a combination thereof. The descriptions contained herein describe methods for inducing weight loss and / or enhancing satiety in subjects. The compositions described herein may be formulated for oral administration and, in some embodiments, may further include an enteric-coated or pH-responsive coating agent.

To provide an excellent solid composition containing bromhexine or a salt thereof and ascorbic acid or a derivative thereof or a salt thereof, wherein the decrease in the content of bromhexine or a salt thereof over time is suppressed. [Solution] We unexpectedly discovered that adding a specific component to a solid composition containing bromhexine or its salts, ascorbic acid or its derivatives, or their salts suppresses the time-dependent decrease in the content of bromhexine or its salts. In other words, the solid composition is characterized by containing (a) bromhexine or a salt thereof, (b) ascorbic acid or a derivative thereof or a salt thereof, and (c) at least one selected from the group consisting of dextromethorphan or a salt thereof, noscapine or a salt thereof, tipepidine or a salt thereof, carbocysteine, guaifenesin, guaiacol or a salt thereof, dimemorphan or a salt thereof.

Disclosed herein are compositions comprising two or more of GLP-1R agonists. The description contained herein describes methods for promote weight loss, maintain healthy weight, prevent weight gain after ceasing use of the pharmaceutical products, reduce appetite cravings / boost satiety, and manage a healthy appetite by increasing GLP-1 levels in a subject. The compositions described herein may be formulated for oral administration, and in some embodiments, may further comprise enteric or pH-responsive coatings.

The present disclosure relates to the treatment of achondroplasia using retinoic acid receptor (RAR) antagonists.

The present application relates to the technical field of separation and purification of Schizonepeta tenuifolia Briq, and relates to a biphenyl compound in Schizonepeta tenuifolia Briq, a preparation method thereof and application of the biphenyl compound as an anti-inflammatory drug. The biphenyl compound in Schizonepeta tenuifolia Briq is obtained by the following steps: soaking Schizonepeta tenuifolia Briq, heating and reflux extraction, recovering and concentrating under reduced pressure, obtaining total extract of Schizonepeta tenuifolia Briq, extracting and concentrating with petroleum ether, dichloromethane and ethyl acetate, obtaining a dichloromethane part extract, gradient elution separation of the dichloromethane part extract, gradient elution separation of the fourth fraction of the obtained eight fractions, gradient elution separation of the third fraction of the obtained six fractions, gradient elution separation of the fifth fraction of the obtained eight fractions, purification and separation of the eluate, and collection of the eluate, and the biphenyl compound in Schizonepeta tenuifolia Briq is obtained at 16.4 minutes. The present application discloses the biphenyl compound in Schizonepeta tenuifolia Briq for the first time, and in vitro anti-inflammatory pharmacodynamic experiments are carried out, which prove that the biphenyl compound has a certain inhibitory effect on RAW264.7 cells and can be applied to preparation of anti-inflammatory drugs.

Described herein are methods for preventing non-injurious cell damage during exposure of a subject to radiation. In some embodiments, the method can include administering to the subject an amount of poloxamer 188 or a pharmaceutical formulation thereof prior to exposure to the insult.

Disclosed herein are compositions / pharmaceutical compositions and kits comprising a peptide and a stabilizer; wherein the peptide comprises an ester and is between 2 and 10 amino acids long; and wherein the stabilizer is selected from: a diol, a polyol, a mono-saccharide, a di- saccharide, an oligo-saccharide, and a poly-saccharide, including any combination thereof.

The present application relates to a kind of biological ortho prodrug, composition and its application, specifically disclose a kind of drug prodrug with substituted acrylamide or substituted vinyl sulfonamide structure, is obtained by the reaction of covalent warhead comprising active drug and N-alkyl hydroxylamine.The drug prodrug can be released by Retro-Cope elimination reaction and Cope elimination reaction with tension alkyne, and the release rate can reach more than 90%, to realize on-demand activation active warhead, effectively solve the off-target problem of covalent inhibitor.In addition, by introducing the drug or fluorophore containing hydroxyl / amine group in the propargyl position of tension alkyne, the intermediate produced after Cope elimination reaction of tension alkyne can further undergo elimination reaction, release the drug or fluorophore containing hydroxyl / amine group, realize combined therapy or real-time monitoring of drug release.The above-mentioned drug prodrug and the composition formed by the combination of tension alkyne have good application prospect in the preparation of drug delivery system or active drug.

This study provides a preparation method of paclitaxel-paeoniflorin nanosize co-amorphous complex and its application. The nanosize preparation (NPs) obtained by anti-solvent precipitation method has a particle size of about 150 nm and a uniform distribution after process optimization. The characterization results show that PTX and PTE form a co-amorphous structure through hydrogen bonding. The NPs significantly improve the dissolution rate of PTX, with a peak concentration about 7 times that of the raw material. In vitro cell experiments show that PTX-PTE NPs exhibit enhanced cytotoxicity to A549 cells and their paclitaxel-resistant strain A549 / T, and can reverse multidrug resistance by down-regulating P-gp and CDK1 protein expression. This study provides a new strategy for improving the properties of poorly soluble drugs and combination therapy.

This invention belongs to the field of biomedical technology, specifically relating to the application of phyllanthin (PHY) in the preparation of drugs for the treatment or prevention of colitis. The technical problem this invention aims to solve is to provide a new option for the treatment of colitis. The technical solution of this invention is the application of phyllanthin (PHY) in the preparation of drugs for the treatment or prevention of colitis, ulcerative colitis, or Crohn's disease. This invention is applicable to the treatment or prevention of colitis, providing a treatment solution with both "anti-inflammatory" and "barrier repair" functions.

The present application relates to a drug delivery system for improving tumor microenvironment and a preparation method and application thereof, the drug delivery system comprises liposomes, an anti-tumor drug loaded in the liposomes and a polymer particle wrapped in the core of the liposomes; the components of the polymer particle comprise PC7A polymer and Poly(I:C) polymer; the anti-tumor drug is selected from an RXR alpha agonist, an ITPR2 inhibitor or an MCU inhibitor; the RXR alpha agonist is selected from aurorex, SR11237, CD3257, GW0791 or an isomer of the foregoing drug, or a pharmaceutically acceptable salt of the foregoing drug. The drug delivery system can maintain stability for a long time under in-vivo and in-vitro physiological conditions, and quickly release the loaded anti-tumor drug molecules into the cytoplasm, help them to realize lysosome escape, and effectively enter the cytoplasm. When delivering the anti-tumor drug molecules, the delivery system exhibits excellent tumor microenvironment regulation ability, can effectively participate in inhibiting T cell exhaustion, and improves the efficiency of anti-tumor immunotherapy.

The present invention relates to a group of resorcinol derivatives as a pharmaceutically active compounds and methods of preparation thereof. Resorcinol derivatives have been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of the resorcinol derivative of the invention.

[Summary] The present invention relates to an AMPK activator comprising 1,1-diethoxyethane (1,1-DEE) as an active ingredient and the uses thereof. More specifically, the present invention relates to an AMPK activator comprising 1,1-diethoxyethane as an active ingredient and the uses thereof, for example, compositions for preventing, treating, or improving diseases requiring AMPK activation, anti-aging, extending lifespan, or enhancing physical vitality, including pharmaceutical compositions, cosmetic compositions, food compositions, or feed compositions. The present invention also relates to a composition for improving insulin resistance comprising 1,1-diethoxyethane (1,1-DEE) as an active ingredient and the uses thereof. More specifically, the present invention relates to a composition comprising 1,1-diethoxyethane as an active ingredient as an oxidative PTEN inhibitor for increasing insulin sensitivity or improving insulin resistance, and the uses thereof, for example, compositions for preventing, treating, or improving diseases associated with insulin resistance, including pharmaceutical compositions, cosmetic compositions, food compositions, or feed compositions. The present invention further relates to a composition for preventing or treating obesity or related metabolic disorders comprising 1,1-diethoxyethane (1,1-DEE) as an active ingredient. More specifically, the present invention relates to pharmaceutical compositions, cosmetic compositions, food compositions, or feed compositions comprising 1,1-diethoxyethane as an active ingredient for preventing or treating obesity.

This invention relates to the field of breast cancer therapeutics, providing a novel application of *Dendrobium nobile*, specifically the application of dendrobine in the preparation of breast cancer therapeutics. This invention verifies that dendrobine can significantly inhibit breast cancer cell viability. The inhibitory effect of dendrobine on the migration and proliferation of T47D breast cancer cells and its ability to induce cell death increases with increasing dosage. Simultaneously, cloning experiments also show that dendrobine significantly inhibits the colony-forming ability of breast cancer cells. ROS and JC-1 experiments also show that dendrobine induces mitochondrial dysfunction and increases ROS levels. Western blot experiments show that under dendrobine treatment, the expression levels of ferroptosis markers GPX4 and Nrf2 are significantly reduced. Dendrobine can promote ferroptosis in breast cancer cells and inhibit their cell viability by inducing mitochondrial dysfunction, and it holds promise as a breast cancer therapeutic drug specifically targeting ferroptosis.

Disclosed herein are compositions comprising two or more of GLP-1R agonists. The description contained herein describes methods for promote weight loss, maintain healthy weight, prevent weight gain after ceasing use of the pharmaceutical products, reduce appetite cravings / boost satiety, and manage a healthy appetite by increasing GLP-1 levels in a subject. The compositions described herein may be formulated for oral administration, and in some embodiments, may further comprise enteric or pH-responsive coatings.

The application provides application of CTMB in preparation of a drug for treating and / or preventing a traumatic brain injury disease, a milk injection for treating and / or preventing the TBI disease and a preparation method of the milk injection, and provides an effective, safe and non-toxic drug which can significantly improve the integrity of a blood brain barrier, promote recovery of motor function of a TBI model rat, reduce a neuroinflammatory response, antagonize glutamic excitatory neurotoxicity, reduce neuron apoptosis, improve nerve function defect and emotional anxiety, and has a significant neuroprotective effect on the TBI injury.

The application provides application of CTMB in preparation of a medicine for treating and / or preventing ischemic cerebral stroke, a milk injection for treating ischemic cerebral stroke and a preparation method of the milk injection, and provides a medicine for treating or preventing ischemic cerebral stroke, which can significantly improve the neurological behavior and sensory and motor functions of a model rat of ischemic cerebral stroke, is effective and safe, and has no obvious toxic side effects.

Embodiments of therapeutic protocols to treat Post-Acute Sequelae SARS-COV-2 infection (“PASC”), a.k.a. “long Covid,” are described. The PASC treatment protocols focus on a moderating a hyperimmune response; destroying and removing the SARS COV-2 spike protein from the gut and body, detoxifying the body and the brain; replenishing key nutrients; mitigating depression and anxiety; and a regimen of physical and mental exercises. A standard six-week protocol and a shorter, three-week protocol are disclosed for those with a milder form of PASC are disclosed.

The invention relates to a powder mixture for oral delivery of active ingredients, the powder mixture comprising a population of particles and one or more active ingredients, the population of particles including at least two types of sugar alcohol particles, wherein: at least one of said at least two types of sugar alcohol particles comprising i) non-directly compressible (non-DC) sugar alcohol particles or ii) directly compressible (DC) sugar alcohol particles that are not granulated sugar alcohol particles; at least one of said at least two types of sugar alcohol particles having a particle size with more than 50% of the particles being below 250 microns; and at least one of said at least two types of sugar alcohol particles being present in an amount of at least 20% by weight of the powder mixture.

The present disclosure relates to methods and compositions comprising cannabidiol (CBD) and a volatile anaesthetic, particularly isoflurane, useful for treating or preventing traumatic brain injury (TBI).

To provide a solid preparation containing ibuprofen, tranexamic acid and guaifenesin, where the preparation has reduced failures in appearance.SOLUTION: A solid preparation contains an uncoated tablet containing ibuprofen, tranexamic acid and guaifenesin, and a coating layer covering the uncoated tablet and containing a polyvinyl alcohol.SELECTED DRAWING: None

Syrup formulation have an over-the-counter active pharmaceutical ingredient. The syrup includes water, diphenhydramine HCl in amounts greater than about 4 mg / ml, and sweetener. The sweetener is one or more sweeteners selected from the group consisting of sugars, the sugars being present in amounts greater than about 200 mg / ml, and sugar substitutes, the sugar substitutes being present in amounts greater than about 2 mg / ml. The diphenhydramine HCl is present in concentrated amounts. Multiple doses of the syrups may be packaged in relatively small bottles, such as bottles with a capacity of 100 ml or less.